Integration of pharmaceutical discovery and development : case histories

著者

書誌事項

Integration of pharmaceutical discovery and development : case histories

edited by Ronald T. Borchardt ... [et al.]

（Pharmaceutical biotechnology, v. 11）

Plenum Press, c1998

大学図書館所蔵 件 / 全3件

この図書・雑誌をさがす

注記

Includes bibliographical references and index

内容説明・目次

内容説明

In the late 1980s, it became painfully evident to the pharmaceutical industry that the old paradigm of drug discovery, which involved highly segmented drug - sign and development activities, would not produce an acceptable success rate in the future. Therefore, in the early 1990s a paradigm shift occurred in which drug design and development activities became more highly integrated. This new str- egy required medicinal chemists to design drug candidates with structural f- tures that optimized pharmacological (e. g. , high affinity and specificity for the target receptor), pharmaceutical (e. g. , solubility and chemical stability), bioph- maceutical (e. g. , cell membrane permeability), and metabolic/pharmacokinetic (e. g. , metabolic stability, clearance, and protein binding) properties. Successful implementation of this strategy requires a multidisciplinary team effort, incl- ing scientists from drug design (e. g. , medicinal chemists, cell biologists, en- mologists, pharmacologists) and drug development (e. g. , analytical chemists, pharmaceutical scientists, physiologists, and molecular biologists representing the disciplines of pharmaceutics, biopharmaceutics, and pharmacokinetics/drug metabolism). With this new, highly integrated approach to drug design now widely utilized by the pharmaceutical industry, the editors of this book have provided the sci- tific community with case histories to illustrate the nature of the interdisciplinary interactions necessary to successfully implement this new approach to drug d- covery. In the first chapter, Ralph Hirschmann provides a historical perspective of why this paradigm shift in drug discovery has occurred.

目次

  • Introduction
  • R. Hirschmann. Renin Inhibitors
  • S.H. Rosenberg, H.D. Kleinert. The Discovery and Development of Angiotensin II Antagonists
  • D.J. Carini, et al. Development of an Orally Active Tripeptide Arginal Thrombin Inhibitor
  • R.T. Shuman, P.D. Gesellchen. Discovery and Development of an Endothelin-A Receptor Selective Antagonist PD 156707
  • A.M. Doherty, A.C.G. Uprichard. Endothelin Receptor Antagonists
  • J.D. Elliott, et al. LHRH Antagonists
  • F. Haviv, et al. LHRH Agonists
  • K.W. Funk, et al. Discovery and Development of Somatostatin Agonists
  • P. Marbach, et al. Factors Impacting the Delivery of Therapeutic Levels of Pyrone-Based HIV Protease Inhibitors
  • G.E. Padbury, et al. The Integration of Medicinal Chemistry, Drug Metabolism, and Pharmaceutical Research and Development in Drug Discovery and Development: The Story of Crixivan (R), an HIV Protease Inhibitor
  • J.H. Lin, et al. De Novo Design and Discovery of Cyclic HIV Protease Inhibitors Capable of Displacing the Active-Site Structural Water Molecule
  • G.V. De Lucca, et al. Discovery and Development of the BHAP Nonnucleoside Reverse Transcriptase Inhibitor Delaviridine Mesylate
  • W.J. Adams, et al. 12 Additional Chapters. Index.

「Nielsen BookData」 より

関連文献： 1件中  1-1を表示

詳細情報

ページトップへ